Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
David P. Nicolau, PharmD
Director
Hartford Hospital
Poster(s):
(P-1067)
In Vitro
Potency of Ceftibuten-Avibactam (CTB-AVI) and Comparators against Extended-Spectrum Beta-Lactamase (ESBL)-like Enterobacterales from Outpatient Centers and Nursing Homes in the United States
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1216)
Comparison of the
in vivo
Efficacy and Resistance Development Potential between Cefiderocol (FDC) and Ceftolozane/tazobactam (C/T) Human Simulated Exposures against
Pseudomonas aeruginosa i
n 72 Hour Murine Thigh Infection Model
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1217)
Validation of Cefiderocol (FDC) Package Insert Dosing Recommendation for Patients receiving Continuous Renal Replacement Therapy (CRRT): A Prospective Multi-Center Pharmacokinetic Study
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1219) Benchmarks for Humanized Meropenem Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against
Klebsiella pneumoniae
in Standardized Murine Lung Infection Model
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1220) Humanizing Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures of Cefiderocol in Standardized Murine Lung Infection Model
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1221) Benchmark Efficacy for Humanized Cefiderocol Plasma and Pulmonary Epithelial Lining Fluid (ELF) Exposures Against Gram Negative Isolates in Standardized Murine Lung Infection Model
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1226) Dose Optimization of β-lactams against Carbapenem-Resistant Pseudomonas from Turkiye Defined as Susceptible to Ceftazidime, Cefepime or Piperacillin/Tazobactam
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1227) Population Pharmacokinetics (PK) of Cefiderocol (FDC) during Acute Pulmonary Exacerbations (APE) in Adult Persons with Cystic Fibrosis (CF)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1341) Differential Frequency of Persister cells in Clinically Derived
Pseudomonas aeruginosa
Isolates after Exposure to Cefiderocol (FDC) or Ceftolozane/tazobactam (C/T)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1653) Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) across Outpatient and Urgent Care Visits
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT